AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Looking ahead, Novo Nordisk’s pipeline includes several promising candidates that could further strengthen its position in the metabolic disease space. Amycretin, a once-daily oral GLP-1/Amylin ...

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

In addition, at the end of January 2025, Novo Nordisk published data from a phase 1b/2a clinical study with amycretin, which beat even my wildest expectations. Learn why I believe Novo Nordisk is ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

Novo Nordisk's once-daily oral Amycretin, a GLP-1/Amylin co-agonist, has shown promising results in early trials. With competitive weight loss percentages at various doses compared to other oral ...

Novo Nordisk’s shares rose by 3.8% in US markets ... A recent trial of its next-generation obesity treatment, amycretin, showed positive results, temporarily lifting its share price in January.